MINI FUTURE LONG - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 13:45:20 27/06/2024 BST | ||
| 25.26 EUR / 25.57 EUR | +0.97% |
|
| Current month | +8.77% | ||
| 1 month | +7.75% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 27/06/24 | 25.28 | +0.44% |
| 26/06/24 | 25.17 | +0.68% |
| 25/06/24 | 25 | -1.11% |
| 24/06/24 | 25.28 | +2.27% |
| 21/06/24 | 24.72 | -0.64% |
Delayed Quote Börse Stuttgart
Last update June 27, 2024 at 10:09 am
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MB1RBS |
| ISIN | DE000MB1RBS4 |
| Date issued | 22/12/2022 |
| Strike | 205.1 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 10.95 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 26.02 € |
|---|---|
| Lowest since issue | 9.55 € |
| Spread | 0.31 € |
| Spread % | 1.21% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
474
USD
Average target price
468.3
USD
Spread / Average Target
-1.21%
- Stock Market
- Certificates
- Certificat
